QIAGEN Launches QIAsure Methylation Test to Determine Cervical Cancer Risk

Wednesday, June 15, 2016 Cancer News J E 4
New follow-up assay helps stratify patients with transforming HPV infections

HILDEN, Germany and SALZBURG, Austria, June 14, 2016 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAsure Methylation Test, a novel CE-marked molecular diagnostic test for use in differentiating patients' risk of developing cervical cancer.

The QIAsure Methylation Test is highly complementary to HPV screening tests and follows either a positive high risk HPV test or a finding of abnormal cells in cytology from a Pap smear and can be used on either clinician collected or self-collected samples. Currently available triage options such as HPV genotyping or tissue-based assays often have limited clinical value, or are subjective and in many cases lead to false positives or missed cervical disease. QIAsure testing accurately stratifies cervical cancer risk by detecting and measuring DNA methylation of two specific genes implicated in cervical cancer. In large scale studies, the DNA markers used in this assay have demonstrated reliable additional insights into a patient's individual risk and contributed to decisions on surveillance and treatment. The test is being presented to the public for the first time at EUROGIN 2016, the international conference for the European Research Organization on Genital Infection and Neoplasia, in Salzburg, Austria.

"QIAsure is a highly attractive and complementary addition to our leading HPV franchise," said Thierry Bernard, Senior Vice President and Head of QIAGEN's Molecular Diagnostics Business Area. "It creates a compelling solution for primary screening that includes the leading HPV primary screening test and leading solution for automated sample processing and molecular analysis of cervical samples."

Click here for the full press release


Public Relations: Dr. Thomas Theuringer Senior Director Public Relations +49-2103-29-11826 Email:

Investor Relations: John Gilardi Vice President Corporate Communications and Investor Relations +49-2103-29-11711 Email:




You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Bill to Reverse Opioid Overdose Epidemic Moves For...
Aventria Health Group Launches New Web Site